Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Sold by Krilogy Financial LLC

Krilogy Financial LLC decreased its position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 14.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 94,952 shares of the company’s stock after selling 15,568 shares during the quarter. Krilogy Financial LLC owned approximately 1.36% of Global X Genomics & Biotechnology ETF worth $922,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Atria Investments Inc acquired a new position in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter valued at about $122,000. Rockefeller Capital Management L.P. acquired a new position in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter valued at about $205,000. Sanctuary Advisors LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF during the 2nd quarter valued at about $590,000. Centaurus Financial Inc. acquired a new position in shares of Global X Genomics & Biotechnology ETF during the 2nd quarter valued at about $146,000. Finally, James J. Burns & Company LLC boosted its position in shares of Global X Genomics & Biotechnology ETF by 6.0% during the 3rd quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock valued at $207,000 after acquiring an additional 1,038 shares during the last quarter. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Trading Down 0.1 %

Shares of GNOM opened at $9.60 on Monday. The firm has a market cap of $66.91 million, a P/E ratio of -4.10 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a 12-month low of $9.50 and a 12-month high of $12.53. The company’s 50-day moving average price is $10.17 and its 200 day moving average price is $10.76.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.